Isabl develops cancer diagnostic tests based on whole genome and RNA sequencing data.
Isabl Inc. has raised $2.0M in total funding. The most recent round was Grant. The last funding was announced in April 2023.
Isabl Inc.'s investors include Y Combinator, Two Sigma Ventures, Sand Hill Angels, National Cancer Institute, Evolution VC Partners.
Isabl Inc. is headquartered in New York, United States.
Isabl develops cancer diagnostic tests based on whole genome and RNA sequencing data.
Isabl Inc. is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Isabl Inc. — Funding & Investors." VCBacked, April 1, 2023, https://www.vcbacked.co/company/isabl-inc. Accessed August 14, 2026.
VCBacked. (2023). Isabl Inc. — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/isabl-inc
{{cite web |title=Isabl Inc. — Funding & Investors |url=https://www.vcbacked.co/company/isabl-inc |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated